<DOC>
	<DOC>NCT00380887</DOC>
	<brief_summary>The purpose of this study is to determine bioequivalence and bioavailability of four different Premarin/MPA test formulations versus the current formulation for Prempro.</brief_summary>
	<brief_title>Study Comparing Four New Formulations for Premarin in Healthy Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Estrogens, Conjugated (USP)</mesh_term>
	<criteria>1. Healthy postmenopausal women aged 35 to 70 years 2. Nonsmoker or smoker of less than 10 cigarettes per day 1. History or presence of clotting disorders 2. History or presence of cancer 3. Presence of HIV, hepatitis B or hepatitis C 4. History of drug or alcohol abuse</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>bioavailability</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>marketed product</keyword>
	<keyword>Premarin</keyword>
	<keyword>Medroxyprogesterone acetate</keyword>
	<keyword>MPA</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>vasomotor symptoms</keyword>
</DOC>